FDA grants breakthrough designation to Glytec’s Glucommander Pediatrics

​

The US FDA has granted breakthrough device designation to Glytec’s proposed insulin dosing recommendation algorithm, Glucommander Pediatrics, for hospitalised newborns and infants under two years old.

The post FDA grants breakthrough designation to Glytec’s Glucommander Pediatrics appeared first on Hospital Management.

 

Back to the Featured Stories
FDA grants breakthrough designation to Glytec’s Glucommander Pediatrics

Featured Stories

Cambridge Heartwear receives $243m tender for HeartSense wearable
Viking Therapeutics begins study of oral VK2735 for obesity
Gilead Sciences signs five-year DevOps agreement with Cognizant
FDA clears Abbott’s CardioMEMS HF system updates
First patient dosed in Vial’s Phase Ib trial of IL-13 x TSLP antibody

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us